Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
World Journal of Urology Nov 28, 2019
Kind S, Büscheck F, Höflmayer D, et al. - A tissue microarray comprising samples of 17,747 tumors with annotated clinicopathological and molecular data was immunohistochemically investigated for Claudin-1 (a membrane-tight junction protein and important for the sealing of the paracellular cleft in epithelial and endothelial cells) expression in order to assess the possible significance of Claudin-1 expression in prostate cancer. Results recognized a unique role for Claudin-1 in prostate cancer. Moreover, in a fraction of prostate cancers, the protein was overexpressed and raised Claudin-1 expression levels prognosticated a favorable prognosis in ERG-positive cancer.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries